Pacific Biosciences of California, Inc. Net Fee Amt
Pacific Biosciences of California, Inc. (PACB) had Net Fee Amt of $3.03 thousand as of 2026-08-06, per its S-8 filed 2026-08-07.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-07
- 2026-08-06: Net Fee Amt $3.03K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-06 | $3.03K S-8 · filed 2026-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |